Kala Pharmaceuticals Inc
NASDAQ:KALA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (14.4), the stock would be worth $-0.6 (487% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.7 | $0.15 |
0%
|
| Industry Average | 14.4 | $-0.6 |
-487%
|
| Country Average | 16.7 | $-0.69 |
-548%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Kala Pharmaceuticals Inc
NASDAQ:KALA
|
140.3m USD | -3.7 | -3.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 53.5 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 23.7 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 14.7 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 21.8 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 15.5 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 19.2 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.9 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 17.1 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 10.7 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Kala Pharmaceuticals Inc
Glance View
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 192 full-time employees. The company went IPO on 2017-07-20. The firm's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS product is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS product is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The firm's AMPPLIFY technology uses selectively-sized nanoparticles that each have a coating. The firm also has a pipeline of development programs, including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs.
